Form 10-Q · Quarterly report
Edwards Lifesciences 10-Q, filed Aug 4, 2026
- Filed
- CIK
- 0001099800
- Accession no.
- 0001099800-26-000043
Summary
Edwards Lifesciences reported first-half 2026 net sales of $3.4 billion, up 15.1% year over year, driven primarily by its TAVR and TMTT product groups. The company also disclosed the February 2026 acquisition of Autus Valve Technologies for $128.9 million plus up to $132.5 million in contingent consideration, the May 2026 consolidation of a previously unconsolidated VIE, and several 2026 FDA and CE Mark approvals, while noting uncertainty over U.S. tariffs and their potential mitigation.
Key points
- Net sales for the first six months of 2026 were $3.4 billion, up $444.7 million from the same period of 2025, driven primarily by TAVR and TMTT products.
- Edwards acquired Autus Valve Technologies in February 2026 for $128.9 million plus up to $132.5 million in contingent consideration tied to regulatory and sales milestones.
- The company received FDA approval in January 2026 for the SAPIEN 3 transcatheter pulmonic valve delivery system, in May 2026 for the TRIFORMIS RESILIA surgical tricuspid valve, and 510(k) clearance in June 2026 for the ECLIPTIS left atrial appendage technology.
- Edwards said it is unable to predict future tariff rates or whether it can mitigate the impact of increased U.S. tariffs and non-U.S. retaliatory tariffs.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management's Discussion Overview The following discussion and analysis contains forward-looking statements within the meaning of the federal securities laws and should be read in conjunction with the disclosures we make concerning risks and other factors that may affect our business and operating results. See “Note Regarding Forward-Looking Statements” preceding Part I, Item 1 in this Quarterly Report on Form 10-Q. We are the leading global structural heart disease innovation company, driven by a passion to improve patient lives. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.